Newron Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Newron Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of CHF 47.38. The average 1-year stock price forecast is 288.36% higher than the current stock price, while the lowest is CHF 35.21 (+188.61%) and the highest is CHF 72.86 (+497.21%).

Price Target: CHF 47.38 (+288.36%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	CHF 35.21	CHF 47.38	CHF 40.73	CHF 72.86
Change	+188.61%	+288.36%	+233.85%	+497.21%

* Price targets were last updated on May 4, 2026.

Analyst Ratings

The average analyst rating for Newron Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	4	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	4	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates CHF 48.00 → CHF 44.00	Buy	Reiterates	CHF 48.00 → CHF 44.00	+260.66%	May 4, 2026
Elemer Piros Lucid Capital	Lucid Capital	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Dec 11, 2025

Financial Forecast

Revenue This Year

10.82M

from 19.13M

-43.43%

from 19.13M

Revenue Next Year

44.83M

from 10.82M

314.34%

from 10.82M

EPS This Year

-1.48

from -

EPS Next Year

0.80

from -1.48

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	5.76M	6.09M	9.06M	51.39M	19.13M	10.82M
Revenue Growth	9.59%	5.76%	48.62%	467.41%	-62.78%	-43.43%
Gross Profit	5.76M	6.09M	9.06M	51.39M	19.13M	10.82M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Income	-12.36M	-13.30M	-11.63M	26.17M	-4.70M	-30.17M
Net Income	-14.90M	-17.49M	-16.22M	15.84M	-13.24M	-31.17M
EPS	-	-	-	-	-	-1.48
Free Cash Flow	-10.04M	-9.64M	-9.22M	-26.67M	39.32M	74.00M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	18.2M
Avg	10.8M
Low	4.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-4.8%
Avg	-43.4%
Low	-77.6%

EPS Forecast

EPS	2026	2027	2028
High	-1.04
Avg	-1.48
Low	-2.23

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-